There are limitations in this study, Ki67 data were lacking for some BC patients which decreased the number of cases in the molecular subtyping; moreover, this case–control study did not clarify the underlying mechanisms beyond the effect of MIF polymorphisms on BC risk. The gene discussed is MKI67; the disease is breast cancer.